Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. The Company is focused on delivering important new therapies to the millions of patients living with chronic skin conditions. Its goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology. The Company's portfolio includes three late-stage product candidates, Cimzia (certolizumab pegol), for the treatment of moderate to severe plaque psoriasis, DRM04, for the treatment of hyperhidrosis, or excessive sweating and DRM01, a topical sebum inhibitor for acne.

Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2011
Size (employees)
95 (est)+54%
Dermira was founded in 2011 and is headquartered in Menlo Park, US

Key People at Dermira

Thomas G. Wiggans

Thomas G. Wiggans

Co-Founder & CEO
Kin Chan

Kin Chan

Vice President of Engineering
Janice Drew

Janice Drew

Vice President & Project Management
Eugene A. Bauer

Eugene A. Bauer

Founder & Chief Medical Officer
Chris Griffith

Chris Griffith

Founder & Vice President, Corporate Development & Strategy
Hans Hofland

Hans Hofland

VP of Research

Dermira Office Locations

Dermira has an office in Menlo Park
Menlo Park, US (HQ)
275 Middlefield Rd

Dermira Data and Metrics

Dermira Financial Metrics

Dermira's revenue was reported to be $22.5 m in FY, 2016 which is a 208% increase from the previous period.
USD

Revenue (FY, 2016)

22.5 m

Revenue growth (FY, 2015 - FY, 2016), %

208%

Net income (FY, 2016)

(7.4 m)

EBIT (FY, 2016)

(7.9 m)

Market capitalization (19-Jul-2017)

1.2 b

Closing share price (19-Jul-2017)

29.6

Cash (31-Dec-2016)

41.8 m
Dermira's current market capitalization is $1.2 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

7.3 m22.5 m

Revenue growth, %

208%

R&D expense

11 m24.4 m20.9 m

General and administrative expense

3 m5 m9.5 m

Operating expense total

14.1 m31.8 m30.4 m

EBIT

(6.8 m)(31.8 m)(7.9 m)

EBIT margin, %

(436%)(35%)

Interest expense

(39 k)(32 k)

Interest income

125 k178 k504 k

Income tax expense

31 k(622 k)

Net Income

(31.9 m)(78.4 m)(7.4 m)
USDFY, 2014FY, 2015FY, 2016

Cash

55.4 m107.2 m41.8 m

Accounts Receivable

18.8 m

Inventories

1 m2.5 m10.6 m

Current Assets

105.5 m217.2 m284 m

PP&E

192 k386 k1.1 m

Goodwill

771 k771 k771 k

Total Assets

178.2 m221.9 m312.6 m

Accounts Payable

5.6 m9.2 m13.5 m

Current Liabilities

11.9 m25.9 m35 m

Total Liabilities

65.2 m

Additional Paid-in Capital

236.4 m346.6 m497.7 m

Retained Earnings

(82.6 m)(161 m)(250.1 m)

Total Equity

153.6 m185.5 m247.4 m

Financial Leverage

1.2 x1.2 x1.3 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(31.9 m)(78.4 m)(7.4 m)

Depreciation and Amortization

47 k72 k123 k

Inventories

(572 k)(1.2 m)(6.8 m)

Accounts Payable

3.2 m3.6 m4.3 m

Cash From Operating Activities

33.2 m51.9 m(74.1 m)

Purchases of PP&E

(156 k)(202 k)(753 k)

Cash From Investing Activities

(109.5 m)(2.6 m)(130.3 m)

Cash From Financing Activities

174.1 m102.9 m139 m

Interest Paid

117 k123 k123 k
Y, 2016

Financial Leverage

1.3 x

Dermira Market Value History

Dermira Company Life and Culture

You may also be interested in